## Note
nid: 1488847815337
model: AnKingOverhaul
tags: #AK_Original_Decks::Step_1::Zanki_Pharmacology, #AK_Step1_v11::#B&B::11_Hematology::01_Hemostasis::02_Platelet_Activation, #AK_Step1_v11::#B&B::11_Hematology::01_Hemostasis::06_Antiplatelet_Drugs, #AK_Step1_v11::#B&B::11_Hematology::01_Hemostasis::07_Anticoagulants, #AK_Step1_v11::#FirstAid::10_Hematology_Oncology::05_Pharm::07_ADP_receptor_Inhibitors, #AK_Step1_v11::#OME_banner::Basic_Science::13_Hematology_Oncology::11_Hemostasis, #AK_Step1_v11::#Physeo::09_Pharm::17_Hem/Onc_Pharm::ADP_Receptors_Inhibitors, #AK_Step1_v11::#Pixorize::03_Pharm::10_Heme::ADP_Receptor_Inhibitors, #AK_Step1_v11::#SketchyPharm::03_Blood_&_Inflammation::01_Anticoagulants_&_Thrombolytics::03_Antiplatelet_agents, #AK_Step1_v11::^Other::^HighYield::2-RelativelyHighYield
markdown: false

### Text
<div>
  What class of <u>anti-platelet</u> drugs may cause <b>TTP</b> as
  an adverse effect?
</div>
<div>
  {{c1::ADP receptor inhibitors}}
</div>

### Extra
- aka P2Y12 inhibitors
<div>
  <i>Ex -grel suffix / <b>ticlopidine</b> (strongest association
  with)</i>
</div>

### Lecture Notes


### Missed Questions


### Pathoma


### Boards and Beyond


### First Aid
<img src="paste-38255273705475.jpg"><img src=
"paste-362512419651587.jpg"><img src="paste-372133146394627.jpg">

### Sketchy
<img src="paste-15633680957443.jpg"> <img src=
"Screen%20Shot%202019-09-23%20at%209.07.36%20AM.png"> <img src=
"Screen%20Shot%202019-09-23%20at%209.08.10%20AM.png"> <a href=
"https://dashboard.sketchy.com/study/medical/courses/medical-pharmacology/units/medical-pharmacology-blood-inflammation/videos/medical-pharmacology-blood-and-inflammation-anticoagulants-and-thrombolytics-antiplatelet-agents?utm_source=anki&utm_medium=partnership&utm_campaign=february_update&utm_content=medical">
Watch Antiplatelet agents</a>

### Pixorize


### Physeo


### OME
<div class="ome-widget">
  <a href=
  "https://onlinemeded.org/spa/heme-onc/hemostasis/acquire?ref=anki">
  <img src="_OME_AnkiFlashcards_Lesson_2.png"></a>
</div>

### Additional Resources


### One by one

